# PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC

> **NCT03829007** · PHASE1,PHASE2 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 33 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DIAGNOSTIC_TEST:** PD-L1 imaging
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT03829007
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-15
- **Primary completion:** 2020-12-17
- **Final completion:** 2021-12-09
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2022-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03829007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03829007, "PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03829007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*